2026 is the year of not only AI really taking over (are you feeling it?) but also the Oral GLP-1 Competition heating up. 🔥

Novo just launched their Wegovy pill and hit over 18,000 prescriptions within its first two weeks. Lilly's likely approval comes in April. And last week, Corxel raised $287M to fund a third contender.

The stakes are obvious: whoever cracks the pill wins the mass market. But there's a problem nobody's solved yet—and it's not efficacy. It's keeping the drug down.

Subscribe to keep reading

This content is free, but you must be subscribed to The Longevity Letter to continue reading.

Already a subscriber?Sign in.Not now

Reply

Avatar

or to participate